文献速递临床试验与 GCP基础与转化研究

甲状旁腺激素(1-34)联合全身振动运动治疗骨质疏松(PaVOS)随机对照试验研究方案

The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of OSteoporosis (PaVOS)- study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-03-16

PaVOS是一项多中心、评估者盲法、优效性、两臂随机对照试验,纳入40名50岁及以上开始使用PTH 1-34治疗的绝经后女性,随机分为PTH 1-34联合全身振动运动组或单用PTH 1-34组。干预组每周三次全身振动运动(每次12分钟,运动与休息比1:1,30 Hz,振幅1 mm),持续12个月,两组均接受PTH 1-34治疗(20 μg皮下注射每日一次)24个月。主要终点为全髋和腰椎骨密度。

要点

  • 联合全身振动运动可能增强PTH 1-34对骨和肌肉的效益并降低骨折风险。
  • PTH 1-34(20 μg皮下注射每日一次)治疗24个月,振动运动干预12个月后二次随机决定是否继续。
  • 主要结局为双能X线吸收法测量的全髋和腰椎骨密度,次要结局包括骨微结构、骨强度及功能指标。

核心结论

  • PaVOS将研究全身振动运动联合PTH 1-34对绝经后骨质疏松女性骨参数的影响。

研究设计与样本

  • 多中心、评估者盲法、优效性、两臂随机对照试验。
  • 纳入40名50岁及以上开始使用PTH 1-34的绝经后女性,随机分为联合组或单药组,两组均接受PTH 1-34(20 μg皮下注射每日一次)24个月。
  • 联合组每周三次全身振动运动(每次12分钟,运动与休息比1:1,30 Hz,振幅1 mm)12个月,之后二次随机决定是否继续振动运动12个月。

关键数值与推荐

  • 主要终点为全髋和腰椎骨密度,采用双能X线吸收法测量。
  • 次要终点包括桡骨和胫骨高分辨率外周定量CT评估的骨微结构和估计骨强度。
  • 检测血清骨转换标志物CTX、P1NP和硬化素,以及功能生物标志物TUG、SPPB、握力和腿伸展功率。
  • 通过问卷评估生活质量(EQ-5D)、身体活动(IPAQ)和跌倒恐惧(FES-I),并收集依从性和跌倒发生率数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PaVOS is a randomized controlled trial (RCT) which aims to address the use of whole-body vibration exercise (WBV) in combination with parathyroid hormone 1-34 fragment teriparatide (PTH 1-34) treatment in patients with osteoporosis. PTH 1-34 is an effective but expensive anabolic treatment for osteoporosis. WBV has been found to stimulate muscle and bone growth. Animal studies have shown a beneficial effect on bone when combining PTH 1-34 with mechanical loading. A combined treatment with PTH 1-34 and WBV may potentially have beneficial effects on bone and muscles, and reduce fracture risk. METHODS/DESIGN: PaVOS is a multicenter, assessor-blinded, superiority, two-armed randomized controlled trial (RCT). Postmenopausal women (n = 40, aged 50 years and older) starting taking PTH 1-34 from outpatient clinics will be randomized and assigned to a PTH 1-34 + WBV-exercise group (intervention group), or a PTH 1-34-alone group (control group). The intervention group will undergo WBV three sessions a week (12 min each, including 1:1 ratio of exercise: rest, 30 Hz, 1 mm amplitude) for a 12-month intervention period. Both the intervention and the control group will receive PTH 1-34 treatment (20 μg s.c. daily) for 24 months. After 12 months the WBV group will be re-randomized to stop or continue WBV for an additional 12 months. The primary endpoint, bone mineral density (BMD), will be measured by dual-energy x-ray absorptiometry of the total hip and the lumbar spine. Secondary endpoints, bone microarchitecture and estimated bone strength, will be assessed using high-resolution peripheral quantitative computed tomography (HR-pQCT) of the radius and tibia. Serum bone turnover markers (carboxy-terminal collagen crosslinks (CTX), amino-terminal propeptide of type-I collagen (P1NP), and sclerostin) and functional biomarkers (Timed Up and Go (TUG), Short Physical Performance Battery (SPPB), grip strength, and leg extension power) will be measured to assess the effect on bone turnover, muscle strength, balance, and functionality. Quality of life (EQ-5D), physical activity (IPAQ) and fear of falling (FES-I) will be assessed by questionnaires. Data on adherence and falls incidence will be collected. DISCUSSION: The PaVOS study will investigate the effects of WBV in combination with PTH 1-34 on bone parameters in postmenopausal women. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02563353 . Registered on 30 September 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jepsen DB, Ryg J, Jørgensen NR, et al. The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of OSteoporosis (PaVOS)- study protocol for a randomized controlled trial. Trials. 2018. PMID: 29548300. doi:10.1186/s13063-018-2551-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。